Colorectal News and Research

RSS

MedImmune to present ten abstracts at American Association for Cancer Research meeting

MedImmune today announced that ten abstracts on progress being made in various oncology programs will be presented during the Annual Meeting of the American Association for Cancer Research in Washington, DC from April 17 to 21.

17 Apr 2010

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26-week) toxicology study of CEQ508 – the company's lead drug candidate based on its proprietary tkRNAi technology. This study is designed to enable a Phase II clinical trial slated for 2011. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.

16 Apr 2010

Low income and lack of health insurance result in fewer rate of colorectal cancer screening

High out-of-pocket costs, lack of health insurance and limited access to care contribute to a relatively low rate of colorectal cancer screening in the United States, according to a new systematic review by researchers at the RTI International-University of North Carolina at Chapel Hill Evidence-based Practice Center.

16 Apr 2010

Current screening methods for FOBT are often not appropriate

More than 75 percent of primary care physicians in the United States who order or perform the fecal occult blood test as a screening option for colorectal cancer perform an in-office test rather than relying on the home-based test, even though the home-based test is more accurate, a study by the Centers for Disease Control and Prevention has found.

16 Apr 2010

Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma and refractory advanced colorectal cancer.

15 Apr 2010

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Pfizer Oncology announced today that it will present new data from the company's pipeline, including two novel, dual PI3K/mTOR inhibitors (PF-04691502 and PKI-587, also known as PF-05212384); crizotinib (PF-02341066), an ALK inhibitor that also inhibits c-MET; and PF-04605412, an anti-α5β1 inhibitor.

15 Apr 2010

Enrollment complete in Jennerex' Phase 1 trial of JX-594 IV administration for solid tumors

Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced that it has completed patient enrollment in a Phase 1 clinical trial evaluating the intravenous (IV) administration of JX-594, the company's lead product for the treatment of solid tumors. Jennerex expects to report the results from this trial at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in May 2010.

15 Apr 2010

Inflammasome components help protect against colitis

Particular components of inflammasomes-protein complexes needed for generating immune responses to pathogens and cellular damage-lessen the severity of colitis and colitis-associated colon cancer in mice, according to a study published online this week in the Journal of Experimental Medicine.

13 Apr 2010

Over 17,000 scientists convene at AACR 101st Annual Meeting 2010

Scientific breakthroughs in molecular targeting, translational cancer research and cancer prevention will take center stage when more than 17,000 scientists from around the world gather at the Walter E. Washington Convention Center, April 17-21, for the AACR 101st Annual Meeting 2010.

13 Apr 2010

SAGES 2010: Covidien to showcase technological advancements in bariatric, colorectal and hernia surgery

Covidien, a leading global provider of healthcare products, will preview a variety of new devices and showcase some of the Company's most innovative tools for endoscopic surgery and soft tissue repair at the 2010 Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) annual meeting held here.

13 Apr 2010

Study explains why Hispanics are less likely to undergo colorectal cancer screening

A new study finds that Hispanics live in areas with more limited availability of colonoscopies and sigmoidoscopies for colorectal cancer screening. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that differences in areas' capacity for providing these procedures may explain why Hispanics are less likely to undergo colorectal cancer screening than non-Hispanic whites.

12 Apr 2010

Research shows association between LRP16 expression in colorectal cancer and disease related death

Leukemia related protein 16 gene is an important estrogen-responsive gene. LRP16 gene plays an important role in the carcinogenesis and progression of hormone-dependent cancer. LRP16 expression was also reported to be associated with invasion, metastasis and prognosis of gastric carcinoma. But no comprehensive description of LRP16 protein expression in colorectal cancer has been reported.

12 Apr 2010

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Keryx Biopharmaceuticals, Inc. announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of patients with refractory advanced colorectal cancer.

9 Apr 2010

Æterna Zentaris commences perifosine Phase 3 registration trial

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced the initiation of a Phase 3 registration clinical trial with perifosine (KRX-0401) ), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer.

9 Apr 2010

Obese patients may receive higher rate of recommended care than normal-weight patients, but not lower

Despite a concern that obese or overweight patients may receive lower quality of health care, an analysis of eight common outpatient quality measures from a sample of nearly 70,000 patients finds no evidence that obese or overweight patients receive inferior care when compared with normal-weight patients, and in fact may receive a higher rate of recommended care on several measures, according to a study in the April 7 issue of JAMA.

8 Apr 2010

Secretary of Health announces five health research grants to improve health of Pennsylvanians

Secretary of Health Everette James today announced five health research grants totaling approximately $20 million will be awarded from Pennsylvania's share of the national tobacco settlement for 2009-2010.

8 Apr 2010

Expert testimony at Patel manslaughter trial

In the trial of Dr Jayant Patel an expert surgeon who testified last week was cross examined by the defence lawyers. Patel is currently on trial in the Supreme Court in Brisbane for the manslaughter of three patients and causing grievous bodily harm to a fourth.

7 Apr 2010

Investment report on Keryx Biopharmaceuticals from BeaconEquity.com

BeaconEquity.com announces an investment report featuring Keryx Biopharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 Apr 2010

Par Pharmaceutical, sanofi-aventis resolve patent litigation case

Par Pharmaceutical Companies, Inc. today announced that it (and its subsidiary Par Pharmaceutical and development partner MN Pharmaceuticals of Turkey) has entered into a settlement agreement with sanofi-aventis that resolves patent litigation related to its generic version of sanofi's and Debiopharm's Eloxatin® (oxaliplatin injection) product, a drug used to treat colorectal cancer, in the U.S. District Court for the District of New Jersey.

6 Apr 2010

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer.

5 Apr 2010

Colorectal News and Research

MedImmune to present ten abstracts at American Association for Cancer Research meeting

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

Low income and lack of health insurance result in fewer rate of colorectal cancer screening

Current screening methods for FOBT are often not appropriate

Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Enrollment complete in Jennerex' Phase 1 trial of JX-594 IV administration for solid tumors

Inflammasome components help protect against colitis

Over 17,000 scientists convene at AACR 101st Annual Meeting 2010

SAGES 2010: Covidien to showcase technological advancements in bariatric, colorectal and hernia surgery

Study explains why Hispanics are less likely to undergo colorectal cancer screening

Research shows association between LRP16 expression in colorectal cancer and disease related death

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Æterna Zentaris commences perifosine Phase 3 registration trial

Obese patients may receive higher rate of recommended care than normal-weight patients, but not lower

Secretary of Health announces five health research grants to improve health of Pennsylvanians

Expert testimony at Patel manslaughter trial

Investment report on Keryx Biopharmaceuticals from BeaconEquity.com

Par Pharmaceutical, sanofi-aventis resolve patent litigation case

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News